In a recent study published in Cell Reports, a team of scientists from Gilead Sciences Inc. and the University of Cincinnati detail the discovery and engineering of potent bispecific antibodies that can significantly reduce lesion development in a guinea pig model of recurrent genital herpes.
Assembly Biosciences Inc. has disclosed bicyclic heterocycle compounds reported to be useful for the treatment of cytomegalovirus (CMV) and herpes simplex virus (HSV) infections.
Aicuris Anti-infective Cures AG has announced its intention to focus on the development and commercialization of anti-infectives for immunocompromised individuals, and will discontinue research activities outside of this strategic scope.
Symbio Pharmaceuticals Ltd. has entered into a sponsored research agreement with Tufts University to conduct joint research on the intravenous formulation of the antiviral drug brincidofovir.
A team of researchers has created peptide-like molecules – "peptoids" – with antiviral properties that could circumvent the naturally occurring antimicrobial peptides' shortcomings.
A German-American team of researchers has developed a compound that could affect latent herpes simplex virus (HSV) infections, reducing the risk of recurrence even after an infection had fully established itself in its neuronal reservoir.
